In this section
Clinical Trials
Research studies
Clinical trials
Listing updated: 19 April 2024
Trial title |
Blood cancer type |
Therapy history |
Current trial status |
A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects with Large Granular Lymphocytic Leukaemia or Cytotoxic Lymphomas |
Lymphoma (at least one prior line) |
Recruiting | |
A Phase Ib/II Open-Label Study of APG2575 in Combination with Novel Therapeutic Regimens in Subjects with Relapsed or Refractory Multiple Myeloma and Immunoglobulin Light Chain Amyloidosis |
|
Relapsed/refractory multiple myeloma or AL amyloidosis previously treated with at least 1 line of prior therapy |
Recruiting |
Phase 1-2 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents compared to isatuximab with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma (RRMM) |
Relapsed multiple myeloma |
At least 3 prior lines including Pis and IMiDs or at least 2 prior lines if at least one of these lines consisted of 2 or more multiagent regimens |
Recruiting |
A Phase 1 Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-2575 in Patients with Hematologic Malignancies |
|
Relapsed, refractory or intolerant to standard therapy | Recruiting |
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK)-Inhibitor | Myelofibrosis | Intermediate-2 or High-risk Myelofibrosis Refractory to JAK Inhibitor | Recruiting |
An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an anti-CD20 x anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma |
|
Relapsed/refractory to at least two prior lines of therapy including anti-CD20 antibody and an alkylating agent |
Recruiting |
A Phase 1a/1b Study of PSB202 in patients with previously treated-, relapsed-, indolent B Cell Malignancies |
|
Relapsed or refractory to at least two prior lines of therapy | Recruiting |
A Randomized, 2-Arm, Phase 3 Study Of Elranatamab (PF-06863135) vs Lenalidomide In Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Undergoing Autologous Stem-Cell Transplantation |
Newly diagnosed multiple myeloma after autologous stem cell transplantation |
Autologous stem cell transplantation | Recruiting |
A Phase 3, Randomized, Multicenter, Open-Label Study Comparing Iberdomide, Daratumumab, and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) |
Relapsed or refractory multiple myeloma |
Relapsed or refractory to 1-2 prior lines of therapy | Recruiting |
Phase 1/2 study with an open-label dose escalation phase followed by a randomised, double-blind phase of SLN124 in patients with Polycythemia Vera | Polycythemia Vera | Recruiting | |
An Open-Label, 2-Arm, Multicenter, Randomized Phase 3 Study To Evaluate The Efficacy And Safety of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Lenalidomide + Dexamethasone in Transplant-Ineligible Participants With Newly-Diagnosed Multiple Myeloma | Newly diagnosed multiple myeloma | No prior therapy and ineligible for transplant | Recruiting |
A Dose Escalation and Expansion Study of ABBV-383 in Combination with Anti-Cancer Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma | Relapsed/refractory multiple myeloma | At least 3 prior lines of therapy | Recruiting |
First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects with Relapsed or Refractory Multiple Myeloma |
Relapsed/refractory multiple myeloma | Previous treatment with a proteasome inhibitor, immunomodulatory agent and an anti-CD38 antibody | Recruiting |
First-in-human, open label Phase 1/2 study to investigate safety and efficacy of SAR445515, an NK-cell-engager (NKCE) targeting B-cell maturation antigen (BCMA) in monotherapy in participants with relaped/refractory multiple myeloma (RRMM) and in relapsed/refractory light-chain amyloidosis (RR LCA) |
Relapsed/refractory multiple myeloma and relapsed/refractory light chain amyloidosis | Myeloma: at least 2 prior lines of therapy including a proteasome inhibitor, immunomodulatory agent and an anti-CD38 antibody Amyloidosis: at least 1 prior line of therapy including a proteasome inhibitor |
Recruiting |
A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing CC-92480 (BMS-986348), Carfilzomib, and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) | Relapsed/refractory multiple myeloma | At least 1 prior line of therapy including lenalidomide and an anti-CD38 antibody | Recruiting |
International, multi-center, open-label, treatment extension study in patients with multiple myeloma who are still benefitting from isatuximab-based therapy following completion of a Phase 1, 2, or 3 parental study | Relapsed/refractory multiple myeloma | Completed a phase 1, 2 or 3 parental study of isatuximab | Recruiting |
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) | Diffuse large B-cell lymphoma, high-grade B-cell lymphoma, transformed follicular lymphoma or primary mediastinal large B-cell lymphoma | Maximum 1 prior line of therapy including an anti-CD30 and anthracycline | Recruiting |
A phase 3, open-label, randomized study to compare the safety and efficacy of Odronextamab (REGN1979), an anti-CD20 x anti-CD3 bispecific antibody, versus investigator’s choice in previously untreated participants with Follicular lymphoma (OLYMPIA-1) | Follicular lymphoma | No prior therapies | Recruiting |
A Phase 3, Open label, Randomized Study Comparing the Safety and Efficacy of Odronextamab, an anti-CD20 × anti-CD3 bispecific antibody, in Combination with CHOP (O-CHOP) versus Rituximab in combination with CHOP (R-CHOP) in Previously Untreated Participants with Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3) | Diffuse large B-cell lymphoma | No prior therapies | Recruiting |
A Phase 3, Open-label, Randomized Study to Compare the Safety and Efficacy of Odronextamab Combined with Lenalidomide Versus Rituximab Combined with Lenalidomide in Relapsed/Refractory Indolent Lymphoma (OLYMPIA-5) | Relapsed/refractory follicular lymphoma (grade 1-3a) or marginal zone lymphoma | At least 1 prior line of therapy including an anti-CD20 antibody | Recruiting |
A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | Relapsed/refractory follicular or marginal zone lymphoma | Previously received ≥ 1 line of systemic therapy including anti-CD20 agent | Recruiting |
You can also find up-to-date information on the following platforms:
- ClinTrial Refer App – download and add ‘Haematology Clinical Research Network’ and search for “Epworth Healthcare”
- Cancer Council Victoria - cancervic.org.au/trials and search ‘Epworth Hospital Haematology’
Research studies and clinical data registries - current
The Molecular Oncology and Cancer Immunology (MOCI) pillar of the Centre leads translational, investigator-initiated research in the fields of genomics and cancer immunology. Please contact us if you are interested in taking part in research studies to advance cancer knowledge.
Title |
Category |
Summary |
Key eligibility criteria |
strong>Principal Investigator/s (PI) |
MOCI (Molecular Oncology and Cancer Immunology) Biobank Study |
Investigator-led biobank study |
This study collects and stores de-identified patient blood and tissue samples and clinical information for use in future research projects and clinical studies |
Individuals with haematological or solid tissue malignancies |
Dr CostasYannakou |
ThectDNAProject- Analysis and monitoring of cell free DNA in haematological malignancy |
MOCI-guided service in collaboration with molecular haematology laboratory,Peter MacCallum Cancer Centre |
This project studies patient biomarkers at various stages of their disease while allowing blood cancer patients to access genomic testing that may help guide treatment options |
Individuals with chronic lymphocytic leukemia (CLL), lymphoma and myeloma
|
Dr CostasYannakou Prof Miles Prince Dr Piers Blombery |
CABL Study: Circulating Tumour DNA (ctDNA) as a Biomarker of Response to Anti-cancer Therapy in B-cell non-Hodgkin Lymphoma |
Observational investigator-led study |
This study aims to evaluate the levels of plasma ctDNA before, during and after treatment in patients with B-cell non-Hodgkin lymphoma to assess whether ctDNA levels can be used as a prognostic marker |
Individuals with newly diagnosed or relapsed/refractory B-cell non-Hodgkin lymphoma |
Dr CostasYannakou |
Circulating Tumour DNA as a Biomarker of Tumour Burden in Plasma Cell Dyscrasias (CAMP Study)
|
Observational, investigator-led stud |
This study aims to evaluate the levels of plasma ctDNA before, during and after treatment in patients with plasma cell dyscrasia to assess whether ctDNA levels can be used as a prognostic marker |
Individuals with newly diagnosed or relapsed/refractory multiple myeloma, solitary plasmacytoma or AL amyloidosis |
Dr CostasYannakou |
DENEM Study: Detection of Early Neurotoxicity Using Eyelid Movements |
Observational investigator-led study in collaboration withOptalert |
This study aims to develop methods to classify grades of neurotoxicity in patients undergoing immunotherapyusually associated with neurotoxicity |
Individuals with haematological malignancy planned for immunotherapy, chemotherapy or a haematological disorder not receiving anti-cancer therapy |
Dr CostasYannakou Prof Miles Prince |
Gailey-Lazarus Snowdome Myeloid Fellowship |
Observational investigator-led study in collaboration with the University of Melbourne and Peter MacCallum Cancer Centre |
This Fellowship provides options for patients with myelofibrosis through access to clinical trials. |
Individuals with myeloid disorders |
Dr Indu Raman Dr CostasYannakou |
Lymphoma and Related Diseases Registries (LaRDR) |
Clinical data registry in collaboration with Monash University |
This registry records data from Australia and New Zealand on patient diagnosis and treatment to assist in better understanding of factors that influence patient outcomes |
Individuals with newly diagnosed non-Hodgkin lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia(CLL), and related diseases |
Prof Miles Prince |
ICAN Study: Immunoglobulin use in outcomes in CLL and NHL |
Clinical data registry in collaboration with Monash University and funded by the National Blood Authority |
This registry is sub-study ofLaRDRthat examines immunoglobulin and antibiotic use and infection data which will help guide clinical practice, plan and deliver cost-effective care for better patient outcomes |
Individuals diagnosed with chronic lymphocytic leukemia(CLL) or non-Hodgkin lymphoma that are participating in the LaRDR study |
Prof Miles Prince |
Myeloma and Related Diseases Registry (MRDR) |
Clinical data registry in collaboration with Monash University |
This registry collects current clinical practice data from newly diagnosed patients from Australia and the Asia-Pacific region in the hope of driving improvements beneficial to patients |
Individuals diagnosed with multiple myeloma, MGUS, plasma cell leukaemia or plasmacytoma |
Prof Miles Prince |
M1000 – Biobank sub-project of MRDR |
Biobank repository of blood samples collaboration with Monash University |
This is a sub-study of the MRDR and aims to establish a biobank repository of blood samples from multiple myeloma or MGUS patients for future biomarker studies |
Individuals with newly diagnosed multiple myeloma or MGUS |
Prof Miles Prince |
Opportunistic infections in patients with indolent non-Hodgkin Lymphoma (iNHL) treated with bendamustine +/- anti-CD20 monoclonal antibody |
Retrospective data project investigating treated with bendamustine-based regimens |
This is a retrospective data project performed by the Australasian Lymphoma Alliance (ALA) which aims to collect real-world data to improve clinical care and practice for lymphoma patients. Through Epworth’s membership, MOCI has contributed data to this research project. |
Individuals newly diagnosed and relapsed/refractory patients with indolent NHL or chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) |
Dr CostasYannakou |
Incidence, outcomes and treatment strategies for plasmablastic lymphoma in both HIV positive and negative patients in Australia and New Zealand: 20 years of experience |
Clinical data collection in collaboration with St Vincent’s Hospital Sydney |
Plasmablastic lymphoma is an aggressive disease with poor prognosis. Existing data was collected from patients diagnosed with plasmablastic lymphoma to establish a snapshot of therapeutic practice and outcomes. |
Patients diagnosed with plasmablastic lymphoma |
Dr CostasYannakou |
Factors influencing outcome in Richter’s Transformation; results of a multi-centre retrospective |
A multi-centre retrospective study in collaboration with St Vincent’s Hospital Melbourne |
This multi-centre retrospective cohort study evaluated outcomes in patients with Richter’s transformation; a subset of lymphoma associated with pre-existing CLL/SLL, known to have poor outcomes and currently, there is a lack of treatment consensus
|
Study on Richter’s transformation of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to diffuse large B-cell lymphoma (DLBCL) or Hodgkin lymphoma (HL) |
Dr CostasYannakou |
Lymphoma in pregnant patients: the Australian experience |
A retrospective data project in collaboration with St Vincent’s Hospital Sydney |
This retrospective data project collected clinical information from patients diagnosed with Hodgkin or non-Hodgkin lymphoma during pregnancy or within 12 months postpartum, including a survey of diagnosis, treatment and care experiences |
Patients diagnosed with Hodgkin or non-Hodgkin lymphoma during pregnancy or within 12 months postpartum |
Dr CostasYannakou |
Patterns of care and survival outcomes in relapsed or refractory mantle cell lymphoma (MCL) in Australia. |
Retrospective project in collaboration with Peter MacCallum Cancer Centre |
This retrospective project aims to describe characteristics of the R/R MCL cohort, with aim to develop effective and tolerable treatments. Data was collected from a number of Epworth patients over a short period of time; data is currently under analysis with Peter MacCallum Cancer Centre. |
Patients with relapsed or refractory mantle cell lymphoma (MCL) |
Dr CostasYannakou |